There are currently 31 active clinical trials seeking participants for Non-Alcoholic Fatty Liver Disease research studies. The states with the highest number of trials for Non-Alcoholic Fatty Liver Disease participants are Texas, California, Florida and North Carolina.
Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
NCT06133101
Recruiting
A randomized, controlled study of standard soy milk consumption compared to 2% fat cow's milk consumption in children with Non-alcoholic Fatty Liver Disease (NAFLD). The investigators hypothesize that the daily consumption of soy isoflavones found in the soy milk will be beneficial in reducing NAFLD and other obesity-related comorbidities. The investigators do not expect any adverse endocrine or metabolomic effects from the consumption of soy isoflavones.
Gender:
All
Ages:
Between 5 years and 12 years
Trial Updated:
03/10/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
NCT04807868
Recruiting
The purpose of this study is to create a resource that will advance research that is focused on discovery of novel therapies, risk stratification, and aggressive interventions for those at highest risk for non-alcoholic fatty liver disease (NAFLD). To achieve this, we will generate a biobank of liver tissue collected during standard of care liver biopsies. Paired blood/urine samples, FibroScan and relevant data will also be collected.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: AdventHealth Translational Research Institute, Orlando, Florida
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
NCT05877547
Recruiting
The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Researchers will also learn about the safety and benefit of efinopegdutide and how well people tolerate the medicine. The main goal of the study is to compare how many people taking efinopegdutide or placebo stop showing evidence of NASH without liver scarring getting worse.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/20/2024
Locations: The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 3, Chandler, Arizona +161 locations
Conditions: Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Register for Updates
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
NCT05067621
Recruiting
The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic steatosis in youth with prediabetes/new onset T2D and NAFLD.
Gender:
All
Ages:
Between 10 years and 21 years
Trial Updated:
06/18/2024
Locations: Pediatric Diabetes Center, New Haven, Connecticut
Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
Register for Updates
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
NCT05970640
Recruiting
This study is open to adults with overweight or obesity who also have fatty liver disease. The purpose of this study is to find the highest dose of BI 3006337 that people with overweight or obesity and with fatty liver disease can tolerate. Participants are divided into 4 groups of equal size randomly, which means by chance. Different doses of BI 3006337 are given to participants in each group. Participants in each group receive an injection of either BI 3006337 or placebo once a week. Placebo... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/11/2024
Locations: Velocity Clinical Research, Chula Vista, California +13 locations
Conditions: Non-alcoholic Fatty Liver Disease, Obesity
Register for Updates
Prevention of NAFLD in Hispanic Children
NCT05292352
Recruiting
This is a 2 year clinical trial testing an intensive intervention to reduce dietary sugars as a means to prevent non-alcoholic fatty liver disease (NAFLD) in pre-pubertal Hispanic children.
Gender:
All
Ages:
Between 6 years and 9 years
Trial Updated:
05/30/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
NCT03073343
Recruiting
Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/06/2024
Locations: VA Long Beach Healthcare System, Long Beach, California
Conditions: Non-Alcoholic Fatty Liver Disease, Non Insulin Dependent Diabetes, ALT
Register for Updates
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
NCT05268042
Recruiting
This will be a 6-month randomized clinical trial with two arms: moderately carbohydrate-restricted diet and a fat-restricted control diet. This 6-month study will have 2 phases: a 12-week controlled feeding phase and a 12-week "free living" phase. During the controlled feeding phase, all food will be provided to the families of the participants for the entirety of the 12 weeks. Participants (n=80) will have been diagnosed with NAFLD based on the presence of current evidence of active disease, wh... Read More
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
05/06/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Non-Alcoholic Fatty Liver Disease, Obesity
Register for Updates
The Gut, Liver And Metabolome in Human Immunodeficiency Virus and Non Alcoholic Fatty Liver Disease
NCT06113003
Recruiting
Persons with human immunodeficiency virus (HIV) have higher risk of developing fatty liver disease (NAFLD) than HIV-negative persons but the reasons for this discrepancy are not known. Changes in the intestinal microbiome may contribute to the development of NAFLD in persons with HIV (PWH) through impairment of barrier function of the intestinal wall and by producing metabolites that are harmful to the liver. This project will test the hypothesis that HIV-related NAFLD is associated with differe... Read More
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
05/01/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: HIV, Non-Alcoholic Fatty Liver Disease, Metabolic-Associated Steatotic Liver Disease
Register for Updates
Human Models of Selective Insulin Resistance: Alpelisib, Part I
NCT06354088
Recruiting
The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study will use a drug called alpelisib, which interferes with insulin's actions in the body, to answer the study's main question: does the liver continue to respond to insulin's stimulation of fat production even when it loses the ability to stop making glucose (sugar) in response to insulin. Researchers will compare the impac... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
04/25/2024
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
Register for Updates
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
NCT05979779
Recruiting
This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepatitis (NASH). Six months (26 weeks) of dosing is planned, and subjects will be followed for safety, efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) during this time. The end-of-study visit will take place approximately 4 weeks after the last dose of the study drug (Week 30).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: ProSciento CRU, Chula Vista, California +19 locations
Conditions: Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
Register for Updates
Diet and Meal Timing in Patients With Non-Alcoholic Fatty Liver Disease: A Pilot Study
NCT05332613
Recruiting
This study will assess the impact of time-restricted eating (8 hours of eating each day) with standard of care lifestyle recommendations (hypocaloric, Mediterranean diet and 30 minutes of exercise on at least 5 days/week) on the degree of fat in the liver as measured by magnetic resonance imaging.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/11/2024
Locations: Weill Cornell Medicine, New York, New York
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates